Douglas E. Jorenby

11.7k total citations · 2 hit papers
114 papers, 9.1k citations indexed

About

Douglas E. Jorenby is a scholar working on Physiology, Applied Psychology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Douglas E. Jorenby has authored 114 papers receiving a total of 9.1k indexed citations (citations by other indexed papers that have themselves been cited), including 97 papers in Physiology, 37 papers in Applied Psychology and 32 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Douglas E. Jorenby's work include Smoking Behavior and Cessation (96 papers), Behavioral Health and Interventions (37 papers) and Obesity, Physical Activity, Diet (26 papers). Douglas E. Jorenby is often cited by papers focused on Smoking Behavior and Cessation (96 papers), Behavioral Health and Interventions (37 papers) and Obesity, Physical Activity, Diet (26 papers). Douglas E. Jorenby collaborates with scholars based in United States, China and India. Douglas E. Jorenby's co-authors include Michael C. Fiore, Timothy B. Baker, Stevens S. Smith, Megan E. Piper, David W. Wetter, Susan L. Kenford, Tanya R. Schlam, Stephen I. Rennard, Scott J. Leischow and Thomas M. Piasecki and has published in prestigious journals such as New England Journal of Medicine, JAMA and Circulation.

In The Last Decade

Douglas E. Jorenby

113 papers receiving 8.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Controlled Trial of Sustained-Release Bupropion, a Nicotine Patch, or Both for Smoking Cessation

1999 1.2k citations Douglas E. Jorenby, Scott J. Leischow et al. New England Journal of Medicine profile →
Efficacy of Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking Cessation<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>

2006 1.2k citations Douglas E. Jorenby profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Douglas E. Jorenby United States	50	6.6k	2.6k	2.4k	1.8k	1.0k	114	9.1k
Paul M. Cinciripini United States	49	4.3k 0.7×	1.6k 0.6×	1.4k 0.6×	1.3k 0.7×	1.1k 1.1×	266	8.4k
Stevens S. Smith United States	61	6.6k 1.0×	3.0k 1.2×	2.0k 0.8×	2.0k 1.1×	1.4k 1.4×	159	11.5k
Megan E. Piper United States	49	5.4k 0.8×	2.8k 1.1×	1.5k 0.6×	1.6k 0.9×	1.6k 1.6×	183	9.2k
Karl‐Olov Fagerström Sweden	13	7.8k 1.2×	3.1k 1.2×	2.0k 0.8×	2.3k 1.3×	1.5k 1.4×	25	11.3k
Richard C. Frecker Canada	17	7.1k 1.1×	2.9k 1.1×	1.6k 0.7×	2.3k 1.2×	1.3k 1.2×	31	10.5k
Sharon M. Hall United States	59	7.3k 1.1×	2.9k 1.1×	1.5k 0.6×	2.7k 1.5×	1.0k 1.0×	198	11.7k
Ivana T. Croghan United States	48	3.9k 0.6×	1.0k 0.4×	1.5k 0.6×	1.4k 0.8×	291 0.3×	225	7.0k
Jonathan Foulds United States	46	5.2k 0.8×	1.3k 0.5×	1.4k 0.6×	1.5k 0.8×	383 0.4×	162	6.8k
Janet Audrain‐McGovern United States	40	3.8k 0.6×	1.7k 0.6×	754 0.3×	1.9k 1.1×	711 0.7×	121	7.0k
Cynthia S. Pomerleau United States	42	3.5k 0.5×	1.5k 0.6×	1.5k 0.6×	1.1k 0.6×	683 0.7×	114	6.0k

Countries citing papers authored by Douglas E. Jorenby

Since Specialization

Citations

This map shows the geographic impact of Douglas E. Jorenby's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas E. Jorenby with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas E. Jorenby more than expected).

Fields of papers citing papers by Douglas E. Jorenby

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas E. Jorenby. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas E. Jorenby. The network helps show where Douglas E. Jorenby may publish in the future.

Co-authorship network of co-authors of Douglas E. Jorenby

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas E. Jorenby. A scholar is included among the top collaborators of Douglas E. Jorenby based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas E. Jorenby. Douglas E. Jorenby is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Piasecki, Thomas M., Wendy S. Slutske, Daniel M. Bolt, Douglas E. Jorenby, & Megan E. Piper. (2025). Effects of very low nicotine cigarettes, e-cigarettes, and nicotine patches on daily own-cigarette abstinence in a randomized controlled switching trial. Drug and Alcohol Dependence. 268. 112576–112576. 1 indexed citations

Cook, Jessica W., et al.. (2024). Understanding the motivational mechanisms for smoking and vaping among dual users and exclusive smokers. Drug and Alcohol Dependence. 264. 112436–112436. 1 indexed citations

Schlam, Tanya R., Timothy B. Baker, Megan E. Piper, et al.. (2024). What to do after smoking relapse? A sequential multiple assignment randomized trial of chronic care smoking treatments. Addiction. 119(5). 898–914. 2 indexed citations

Piper, Megan E., et al.. (2023). Dependence motives and use contexts that predicted smoking cessation and vaping cessation: A two-year longitudinal study with 13 waves. Drug and Alcohol Dependence. 250. 110871–110871. 3 indexed citations

Salloum, Ramzi G., Alana M. Rojewski, Megan E. Piper, et al.. (2021). Reporting Treatment Fidelity in Behavioral Tobacco Treatment Clinical Trials: Scoping Review and Measurement Recommendations. Nicotine & Tobacco Research. 24(2). 150–159. 9 indexed citations

Piper, Megan E., Timothy R. Baker, Robin J. Mermelstein, Neal L. Benowitz, & Douglas E. Jorenby. (2020). Relations among cigarette dependence, e-cigarette dependence, and key dependence criteria among dual users of combustible and e-cigarettes.. Psychology of Addictive Behaviors. 36(1). 100–108. 9 indexed citations

Chen, Li‐Shiun, Timothy B. Baker, Ross C. Brownson, et al.. (2016). Smoking Cessation and Electronic Cigarettes in Community Mental Health Centers: Patient and Provider Perspectives. Community Mental Health Journal. 53(6). 695–702. 35 indexed citations

Jorenby, Douglas E., Stevens S. Smith, Michael C. Fiore, & Timothy B. Baker. (2016). Nicotine levels, withdrawal symptoms, and smoking reduction success in real world use: A comparison of cigarette smokers and dual users of both cigarettes and E-cigarettes. Drug and Alcohol Dependence. 170. 93–101. 31 indexed citations

Duster, Megan, Douglas E. Jorenby, Daniel Shirley, et al.. (2016). Feasibility and patient satisfaction with smoking cessation interventions for prevention of healthcare-associated infections in inpatients. Substance Abuse Treatment Prevention and Policy. 11(1). 15–15. 4 indexed citations

10.

Davis, James M., et al.. (2014). Randomized trial comparing mindfulness training for smokers to a matched control. Journal of Substance Abuse Treatment. 47(3). 213–221. 58 indexed citations

11.

Seal, David W., et al.. (2012). Perceptions and Influences of a State Prison Smoking Ban. Journal of Correctional Health Care. 18(4). 293–301. 23 indexed citations

12.

Collins, Linda M., Timothy B. Baker, Robin J. Mermelstein, et al.. (2010). The Multiphase Optimization Strategy for Engineering Effective Tobacco Use Interventions. Annals of Behavioral Medicine. 41(2). 208–226. 219 indexed citations

13.

McElroy, Jane A., Peter M. Vila, Douglas E. Jorenby, et al.. (2009). Peer Reviewed: Smoking, Barriers to Quitting, and Smoking-Related Knowledge, Attitudes, and Patient Practices Among Male Physicians in China. Preventing Chronic Disease. 6(1). 5 indexed citations

14.

Piper, Megan E., Michael C. Fiore, Stevens S. Smith, et al.. (2003). Use of the Vital Sign Stamp as a Systematic Screening Tool to Promote Smoking Cessation. Mayo Clinic Proceedings. 78(6). 716–722. 42 indexed citations

15.

Smith, Stevens S., Douglas E. Jorenby, Scott J. Leischow, et al.. (2003). Targeting smokers at increased risk for relapse: treating women and those with a history of depression. Nicotine & Tobacco Research. 5(1). 99–109. 64 indexed citations

16.

Jorenby, Douglas E.. (2002). Clinical Efficacy of Bupropion in the Management of Smoking Cessation. Drugs. 62(Supplement 2). 25–35. 67 indexed citations

17.

Anderson, Jane, Douglas E. Jorenby, Walter J. Scott, & Michael C. Fiore. (2002). Treating Tobacco Use and Dependence. CHEST Journal. 121(3). 932–941. 165 indexed citations

18.

Jorenby, Douglas E., Scott J. Leischow, Mitchell Nides, et al.. (1999). A Controlled Trial of Sustained-Release Bupropion, a Nicotine Patch, or Both for Smoking Cessation. New England Journal of Medicine. 340(9). 685–691. 1189 indexed citations breakdown →

19.

Jorenby, Douglas E., Dorothy K. Hatsukami, Stevens S. Smith, et al.. (1996). Characterization of tobacco withdrawal symptoms: transdermal nicotine reduces hunger and weight gain. Psychopharmacology. 128(2). 130–138. 116 indexed citations

20.

Fiore, Michael C., Douglas E. Jorenby, Timothy B. Baker, & Susan L. Kenford. (1992). Tobacco dependence and the nicotine patch. Clinical guidelines for effective use.. PubMed. 268(19). 2687–94. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact